RxDoctor Payments Data

Delia Patino, APRN

Psychiatric/Mental Health · Eagle Pass, TXNPI 1528640331

Payments from drug & device makers

$2,955in general payments, 2019–2025

Across 148 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$650
  • AbbVie$428
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$271
  • Johnson & Johnson$209
  • Takeda Pharmaceuticals U.S.A., Inc.$208
  • Eisai Inc.$171
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,84696%
  • Education$1094%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,955 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$6,515
Medicare patients
26
Services billed
134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$75,703
VraylarCariprazine Hcl25$37,540
Paliperidone ErPaliperidone16$3,159
Aripiprazole83$2,866
Duloxetine Hcl135$2,336
Quetiapine Fumarate96$1,815
Desvenlafaxine Succinate ErDesvenlafaxine Succinate35$1,795
Hydroxyzine Hcl60$1,529
Buspirone Hcl116$1,489
Divalproex Sodium ErDivalproex Sodium21$1,167
Mirtazapine66$902
Trazodone Hcl177$852
Bupropion XlBupropion Hcl56$833
Fluoxetine Hcl88$729
Divalproex Sodium22$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$209$75,70327 claims
AbbVieVraylar$428$37,54025 claims
Almatica Pharma LLCSertraline Hcl$12$18984 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →